Thalidomide in refractory and relapsing multiple myeloma

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 588-592

  Blade J ^a   Esteve, J ^a   Rosinol L ^a   Perales, M ^a   Montoto, S ^a   Tuset, M ^a   Montserrat, E ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0035214908     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90029-6     Document Type: Article

References (18)

1. Chemotherapy of myeloma
2. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients
3. Increased conventional chemotherapy does not improve survival in multiple myeloma. Long-term results of two PETHEMA trials including 914 patients
4. Treatment approaches for relapsing and refractory multiple myeloma
5. Bone marrow of patients with active multiple myeloma. Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44
6. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
7. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
8. Bone marrow angiogenesis and progression in multiple myeloma
9. Thalidomide-A revival story
10. Current status of antiangiogenic factors
11. Thalidomide and its analogs overcome drug resistance of human myeloma cells to conventional chemotherapy
12. Antitumor activity of thalidomide in refractory multiple myeloma
13. Therapy with thalidomide in refractory multiple myeloma patients-The revival of an old drug
14. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed multiple myeloma
15. Thalidomide in patients with advanced multiple myeloma
16. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation
17. Thalidomide in multiple myeloma: Lack of response of soft-tissue plasmacytomas
18. Weekly low-dose cyclophosphamide and alternate day prednisone: An effective low toxicity regimen for advanced myeloma